Tobias R Kollmann
Overview
Explore the profile of Tobias R Kollmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
4411
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Castro-Rodriguez J, Fish E, Montgomery S, Kollmann T, Iturriaga C, Shannon C, et al.
EClinicalMedicine
. 2023 Aug;
62:102082.
PMID: 37538539
Background: Accumulating evidence indicates that an early, robust type 1 interferon (IFN) response to SARS-CoV-2 is important in determining COVID-19 outcomes, with an inadequate IFN response associated with disease severity....
12.
Ho R, Bowen A, Blyth C, Imrie A, Kollmann T, Stick S, et al.
Front Immunol
. 2023 Jun;
14:1200456.
PMID: 37304275
The global population has been severely affected by the coronavirus disease 2019 (COVID-19) pandemic, however, with older age identified as a risk factor, children have been underprioritized. This article discusses...
13.
Andualem H, Hollams E, Kollmann T, Amenyogbe N
J Mol Biol
. 2023 Jun;
435(15):168169.
PMID: 37263392
Bacille Calmette-Guérin (BCG) is the most commonly administered vaccine in human history. The medical application of BCG extends far beyond the fight against tuberculosis. Despite its stellar medical record over...
14.
Pittet L, Messina N, Orsini F, Moore C, Abruzzo V, Barry S, et al.
N Engl J Med
. 2023 Apr;
388(17):1582-1596.
PMID: 37099341
Background: The bacille Calmette-Guérin (BCG) vaccine has immunomodulatory "off-target" effects that have been hypothesized to protect against coronavirus disease 2019 (Covid-19). Methods: In this international, double-blind, placebo-controlled trial, we randomly...
15.
Giles M, Way S, Marchant A, Aghaepour N, James T, Schaltz-Buchholzer F, et al.
J Mol Biol
. 2023 Apr;
435(13):168097.
PMID: 37080422
Adverse pregnancy outcomes including maternal mortality, stillbirth, preterm birth, intrauterine growth restriction cause millions of deaths each year. More effective interventions are urgently needed. Maternal immunization could be one such...
16.
Benn C, Amenyogbe N, Bjorkman A, Dominguez-Andres J, Fish E, Flanagan K, et al.
Drug Saf
. 2023 Apr;
46(5):439-448.
PMID: 37074598
The current framework for testing and regulating vaccines was established before the realization that vaccines, in addition to their effect against the vaccine-specific disease, may also have "non-specific effects" affecting...
17.
Strandmark J, Darboe A, Diray-Arce J, Ben-Othman R, Vignolo S, Rao S, et al.
Front Immunol
. 2022 Nov;
13:1043375.
PMID: 36426360
A single birth-dose of Hepatitis B vaccine (HepB) can protect newborns from acquiring Hepatitis B infection through vertical transmission, though several follow-up doses are required to induce long-lived protection. In...
18.
Lee W, Barbosa A, Irwin P, Currie A, Kollmann T, Beaman M, et al.
Trends Parasitol
. 2022 Nov;
39(1):53-69.
PMID: 36400674
Tick-borne diseases (TBDs) are a growing global health concern. Despite extensive studies, ill-defined tick-associated pathologies remain with unknown aetiologies. Human immunological responses after tick bite, and inter-individual variations of immune-response...
19.
Barbosa A, Long M, Lee W, Austen J, Cunneen M, Ratchford A, et al.
Pathogens
. 2022 Nov;
11(11).
PMID: 36365042
In Australia, there is a paucity of data about the extent and impact of zoonotic tick-related illnesses. Even less is understood about a multifaceted illness referred to as Debilitating Symptom...
20.
van den Elsen L, Kollmann T, Verhasselt V
Mucosal Immunol
. 2022 Aug;
15(6):1058-1059.
PMID: 36030351
No abstract available.